Aubuchon Neil William 4

What Happened
Neil W. Aubuchon, Chief Commercial Officer of Viking Therapeutics (VKTX), received a grant of 180,000 derivative shares on January 12, 2026. The filing reports an acquisition price of $0.00 per share (total $0 reported), indicating an equity-based award (options or RSUs) rather than an open-market purchase or sale. This is a compensation grant, not a sale.

Key Details

• Transaction date: 2026-01-12; Form 4 filed 2026-01-26 (filed 14 days after the transaction — late relative to the usual 2-business-day requirement).
• Award: 180,000 derivative shares reported at $0.00 per share (total reported value $0).
• Vesting (footnote): 25% vest immediately; then 25% on each one-year anniversary over the next three years.
• Shares owned after the transaction: not specified in the filing.
• Transaction type code: A (award/grant/other acquisition); this is a compensation grant, not a market purchase.

Context
This is an equity compensation grant that gives Aubuchon the right to receive or acquire 180,000 Viking shares over time as they vest. Because no shares were sold and no cash was paid, it’s a routine executive award used for retention and incentive. The late filing reduces near-term transparency for investors but does not by itself indicate a change in company fundamentals.